Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients who received prior biologics

CSU is characterized by the occurrence of hives or wheals for six weeks or longer ...

Full story available on Benzinga.com